MA-IMABIOTECH
ImaBiotech Group today announced the creation of an innovative global bioanalytical CRO with Pyxant Labs Inc. Colorado Springs and Salt Lake City sites. The integration of the expertise, innovation and analytical platforms of the companies to form a leading global bioanalytical services provider will provide a unique offering to pharmaceutical and cosmetic companies.
Encompassing unique proprietary drug and biomarker imaging (Mass Spectrometry Imaging), multi-omics, spatialomics capabilities and well-established high performance bioanalytical GLP services, the combined platforms will offer access to a unique set of services spanning the drug development cycle, from early-stage discovery through Phase IV. These services reduce the rate of failure and accelerate the development of safer therapies. In conjunction to the operation, the company received a majority investment from ArchiMed SAS (“Archimed”), a leading private equity fund focused on the healthcare sector.
This deal enables a continuing commitment to further extend these specialized capabilities, creating a major player focused exclusively on bioanalytical excellence where the deep-science paradigm, a relentless focus on customer service, and innovative proprietary technology will enable and accelerate therapeutic innovation for our clients.
“I am very pleased to expand our activities in North America and Europe with Pyxant Labs and Archimed,” said former founder and CEO of ImaBiotech, Jonathan Stauber, PhD. “Archimed brings exceptional healthcare expertise with insight into advanced bioanalytical services, and the combination of Pyxant Labs’ established bioanalytical capabilities with ImaBiotech’s innovative imaging technologies will provide a unique service offering to our customers in the US, Europe and Asia, representing a tremendous opportunity to grow in the CRO market.”
“ImaBiotech’s deep-science paradigm and focus on customer service were two essential characteristics in common with our business paradigms, which motivated us toward this combination,” commented Maurice Gaubatz, CEO of Pyxant Labs. "Joining forces with Jonathan’s organization bridges ImaBiotech’s unique mass spectrometry imaging capabilities with Pyxant Labs’ regulatory development bioanalytical services and provides coverage from early research through Phase IV development. The combined enterprise creates an international footprint and leading standing among CROs exclusively focused on mass spectrometry bioanalytical excellence.”
The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2021.
About ImaBiotech www.imabiotech.com
ImaBiotech is a bioanalytical CRO with facilities in Boston (MA, USA) and Lille (Eurasante Park, France). ImaBiotech combines innovative mass spectrometry imaging and spatial biology (histology, multi-omics, spatialomics) techniques in order to decipher the complexity of drug activities. The combination of unique capabilities with advanced digital pathology tools makes possible the measurement of drug activity and drug response, simultaneously, at the single cell level. This performance enables comprehensive drug efficacy evaluation from preclinical to clinical stages.
About Pyxant Labs www.pyxant.com
Founded in 2000, Pyxant Labs provides innovative bioanalytical solutions for advancing leading-edge and challenging drug development programs from translation through NDA approval. Utilizing high resolution mass spectrometry and traditional LC-MS/MS platforms, the Colorado Springs site is recognized for its fast-turnaround drug discovery services, unique expertise quantitating delivery mechanisms for RNA therapeutics, anticipatory customer service, and superior regulatory compliance.
About ArchiMed www.archimed-group.eu
ArchiMed is a leading private equity firm focused exclusively on the healthcare industry. ArchiMed’s strategy is based upon healthcare specialization, integrated private equity, medical and operating expertise, and its unique trans-Atlantic platform that supports growth through internationalization. Over the last 20 years, ArchiMed’s leadership team has directly managed and invested in over 40 small to large-size healthcare companies globally, representing over €5 billion of invested capital. ArchiMed currently manages nearly €2 billion in assets across four funds, small-cap focused MED I and MED II, gene & cell therapy focused PolyMED and mid-cap-focused MED Platform I. The latter is Europe’s largest healthcare fund at €1 billion. ArchiMed is an impact investor and a signatory of the Principles for Responsible Investment , pledged to uphold the United Nations’ Sustainable Development Goals .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005490/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LRN Sponsors 2025 Nordic Ethics & Compliance Survey to Advance Region-Specific Insights on Responsible Business Conduct24.11.2025 10:00:00 CET | Press release
LRN and Nordic Business Ethics partner to elevate region-specific insights that strengthen global E&C effectiveness LRN Corporation, a leader in ethics and compliance (E&C) solutions, announced its sponsorship of the 2025 Nordic Ethics & Compliance Survey, an annual study by Nordic Business Ethics examining how organizations across the Nordic region integrate ethics, responsibility, and compliance into daily decision-making. LRN’s sponsorship supports the survey’s mission to highlight regional insights that enrich global understanding of workplace ethics. The partnership reflects LRN’s belief that effective E&C programs are not a one-size-fits-all solution and must be informed by regional cultural norms and organizational identity. The survey data shows that while Nordic organizations excel in values-driven ethics, their experience mirrors a global trend of increased regulatory expectations and company growth straining operational systems and governance structures. “Nordic organization
IonQ Appoints Dr. Marco Pistoia as CEO of IonQ Italia to Spearhead Strategic Quantum Initiatives Across the Country24.11.2025 09:00:00 CET | Press release
Industry veteran Pistoia to drive enterprise and research engagement as IonQ deepens investment in Italy’s quantum future IonQ (NYSE: IONQ), the world’s leading quantum company, today announced the appointment of Dr. Marco Pistoia, Ph.D., as Chief Executive Officer of IonQ Italia S.r.l., a wholly owned subsidiary. Dr. Pistoia will lead IonQ’s strategic initiatives in Italy, building on the company’s momentum as the world’s only full-stack quantum platform provider across quantum computing, quantum networking, quantum sensing, and quantum security. IonQ Italia will help establish Italy as a dynamic powerhouse in the global quantum landscape. Dr. Pistoia and his team will focus on expanding access to IonQ’s advanced quantum systems for Italian enterprises, research institutions, and government partners. The team will be tasked with driving innovation in quantum applications for key sectors such as finance, energy, aerospace, defense, pharmaceuticals, and advanced manufacturing. “Italy is
Global Youth Invited To Apply for Doha Debates Ambassador Program24.11.2025 07:45:00 CET | Press release
Unique virtual program empowers young changemakers with communication, collaboration, and problem-solving skills Qatar Foundation’s Doha Debates is inviting global youth ages 18–26 to apply for the eighth cohort of its international ambassador program. This 12-week virtual experience empowers participants to engage in constructive dialogue, collaborate on solutions to global challenges and form lasting relationships with other emerging leaders. The application deadline is December 15, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251123068415/en/ Global youth are invited to apply for the Doha Debates Ambassador Program, a unique virtual experience that equips young changemakers with communication, collaboration, and problem-solving skills. (Photo: AETOSWire) The upcoming cohort begins with a four-week Community of Practice from January 20 to February 10, 2026, followed by the official Ambassador Program from February
Brown Brothers Media Acquires European Startup Media Platform Silicon Canals24.11.2025 03:23:00 CET | Press release
Brown Brothers Media, a Singapore-based digital publisher, announces the acquisition of SiliconCanals.com, the European technology startup media platform and community founded by Remco Janssen and operated under Proudly Media. The six-figure, asset-based deal marks a new chapter for the 11-year-old Dutch media brand, which has grown into one of Europe’s leading voices in the startup and innovation ecosystem. Founded in 2014, Silicon Canals has established itself as a go-to source for news and insights on Europe’s tech, venture capital, and startup scene. The acquisition follows recent shifts in the European tech media landscape, including the closure of The Next Web’s editorial operations and MeOut Group’s earlier acquisition of EU-Startups. “After more than a decade building Silicon Canals into a trusted platform connecting Europe’s founders, innovators, and investors, it was time to pass the baton to a full-fledged, long-term media house,” said Remco Janssen, founder and CEO of Proud
IFF Introduces Smart Dosing Robot to Transform Fragrance Production24.11.2025 02:00:00 CET | Press release
New technology delivers quicker, more precise creative sampling for IFF customers across Greater Asia. IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences, has implemented the Colibri robot in its Chin Bee production facility. This advanced industrial dosing system can produce fragrance sample batches on demand in minutes, reimagining and expediting the fragrance development journey for local, regional and global customers in Greater Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251123090457/en/ Photo credit: IFF - Colleagues at IFF Chin Bee with the site's new smart-dosing robot. The new robotic system, installed at the company's cross-category Scent and Taste production plant in Chin Bee, Singapore, accelerates the path from ideation to formulation for fragrance creation. Replacing the previous system, it handles multiple ingredients simultaneously, operates four times
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom